RecruitingPhase 1NCT07283770

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vertex Pharmaceuticals Incorporated
Principal Investigator
Medical Information
Intervention
VX-581(drug)
Enrollment
128 enrolled
Eligibility
18-55 years · All sexes
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07283770 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis

← Back to all trials